Status:
COMPLETED
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
Lead Sponsor:
Alcon Research
Conditions:
Cataract
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction su...
Eligibility Criteria
Inclusion
- ≧18 years of age
- able to sign an informed consent and complete all required visits
- intends to have a cataract extraction surgery followed by implantation of a posterior chamber Intraocular lens (IOL)
- Intraocular Pressure (IOP) ≦ 20 millimeters mercury (mmHg)
Exclusion
- Uncontrolled glaucoma or IOP
- use of ocular anti-infectious during the study and within 30 days prior to the enrollment, secondary implantation or replacement of IOL in the study eye
- use of steroid during the study or within 14 days prior to enrollment
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00870103
Start Date
September 1 2008
Last Update
March 9 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alcon Call Center
Fort Worth, Texas, United States, 76134